OA12770A - Oral dosage form controlled drug release. - Google Patents

Oral dosage form controlled drug release. Download PDF

Info

Publication number
OA12770A
OA12770A OA1200400209A OA1200400209A OA12770A OA 12770 A OA12770 A OA 12770A OA 1200400209 A OA1200400209 A OA 1200400209A OA 1200400209 A OA1200400209 A OA 1200400209A OA 12770 A OA12770 A OA 12770A
Authority
OA
OAPI
Prior art keywords
core
coating
dosage form
oral dosage
erodable
Prior art date
Application number
OA1200400209A
Other languages
English (en)
Inventor
Leung Li Chi
Luigi Martini
Vincenzo Re
Helen Anne Willy
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203298A external-priority patent/GB0203298D0/en
Priority claimed from GB0203297A external-priority patent/GB0203297D0/en
Priority claimed from GBGB0203296.9A external-priority patent/GB0203296D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of OA12770A publication Critical patent/OA12770A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200400209A 2002-02-12 2003-02-12 Oral dosage form controlled drug release. OA12770A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0203298A GB0203298D0 (en) 2002-02-12 2002-02-12 Novel composition
GB0203297A GB0203297D0 (en) 2002-02-12 2002-02-12 Novel composition
GBGB0203296.9A GB0203296D0 (en) 2002-02-12 2002-02-12 Novel composition

Publications (1)

Publication Number Publication Date
OA12770A true OA12770A (en) 2006-07-04

Family

ID=27738830

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400209A OA12770A (en) 2002-02-12 2003-02-12 Oral dosage form controlled drug release.

Country Status (33)

Country Link
EP (1) EP1474114B1 (pt)
JP (2) JP2005526031A (pt)
KR (2) KR101048925B1 (pt)
CN (1) CN100444833C (pt)
AP (1) AP1736A (pt)
AR (1) AR038417A1 (pt)
AT (1) ATE455540T1 (pt)
AU (1) AU2003245763B2 (pt)
BR (1) BRPI0307319B8 (pt)
CA (1) CA2475544A1 (pt)
CL (1) CL2007003010A1 (pt)
CO (1) CO5601025A2 (pt)
CY (1) CY1109939T1 (pt)
DE (1) DE60331041D1 (pt)
DK (1) DK1474114T3 (pt)
EA (1) EA008286B1 (pt)
EC (1) ECSP045232A (pt)
ES (1) ES2336319T3 (pt)
IL (1) IL163098A (pt)
IS (1) IS2747B (pt)
MA (1) MA27689A1 (pt)
MX (1) MXPA04007794A (pt)
MY (1) MY139719A (pt)
NO (1) NO334453B1 (pt)
NZ (1) NZ534152A (pt)
OA (1) OA12770A (pt)
PE (1) PE20030800A1 (pt)
PL (1) PL206596B1 (pt)
PT (1) PT1474114E (pt)
SI (1) SI1474114T1 (pt)
TW (1) TWI286079B (pt)
UY (1) UY27660A1 (pt)
WO (1) WO2003068195A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0120835D0 (en) 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AR045330A1 (es) * 2003-08-07 2005-10-26 Sb Pharmco Inc Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
JP5433236B2 (ja) * 2006-01-27 2014-03-05 アプタリス ファーマテック，インコーポレイテッド 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
US20070196491A1 (en) * 2006-01-27 2007-08-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes

Also Published As

Publication number Publication date
EP1474114B1 (en) 2010-01-20
CY1109939T1 (el) 2014-09-10
JP5279757B2 (ja) 2013-09-04
BRPI0307319B8 (pt) 2021-05-25
NZ534152A (en) 2006-11-30
DE60331041D1 (de) 2010-03-11
EA200401071A1 (ru) 2004-12-30
ES2336319T3 (es) 2010-04-12
PL206596B1 (pl) 2010-08-31
JP2010159301A (ja) 2010-07-22
AU2003245763B2 (en) 2008-12-11
KR20040084900A (ko) 2004-10-06
PL371368A1 (en) 2005-06-13
PE20030800A1 (es) 2003-10-31
SI1474114T1 (sl) 2010-04-30
NO20043633L (no) 2004-10-27
IS2747B (is) 2011-08-15
ECSP045232A (es) 2004-09-28
MY139719A (en) 2009-10-30
CL2007003010A1 (es) 2008-01-25
CA2475544A1 (en) 2003-08-21
AU2003245763A1 (en) 2003-09-04
UY27660A1 (es) 2003-09-30
CO5601025A2 (es) 2006-01-31
MXPA04007794A (es) 2004-10-15
NO334453B1 (no) 2014-03-03
TWI286079B (en) 2007-09-01
AP2004003087A0 (en) 2004-09-30
ATE455540T1 (de) 2010-02-15
DK1474114T3 (da) 2010-04-12
PT1474114E (pt) 2010-03-04
IS7383A (is) 2004-08-05
BR0307319A (pt) 2005-01-04
JP2005526031A (ja) 2005-09-02
BRPI0307319B1 (pt) 2018-05-02
MA27689A1 (fr) 2006-01-02
AR038417A1 (es) 2005-01-12
EA008286B1 (ru) 2007-04-27
CN100444833C (zh) 2008-12-24
CN1655768A (zh) 2005-08-17
WO2003068195A1 (en) 2003-08-21
EP1474114A1 (en) 2004-11-10
AP1736A (en) 2007-05-02
TW200307567A (en) 2003-12-16
HK1072194A1 (en) 2005-08-19
KR101048925B1 (ko) 2011-07-12
IL163098A (en) 2009-05-04
KR20100086084A (ko) 2010-07-29

Similar Documents

Publication Publication Date Title
US9144547B2 (en) Oral dosage form for controlled drug release
JP5279757B2 (ja) 薬物制御放出のための経口用剤形
EP1663191B1 (en) Composition comprising rosiglitazone and metformin
AU2004262926B2 (en) Composition for releasing a weak base for an extended period of time
EP1855671A1 (en) Oral dosage form comprising rosiglitazone
HK1072194B (en) Oral dosage form for controlled drug release
HK1092051B (en) Composition comprising rosiglitazone and metformin